FogPharma Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 68
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $23.3M
Latest Deal Amount
  • Investors
  • 11

FogPharma General Information

Description

Developer of cell-penetrating mini proteins (CPMPs)designed to target cancer-causing proteins inside cancer cells and neutralize them. The company's mini proteins (CPMPs) are a broad new class of medicines that can drug target beyond the reach of conventional therapeutics, enabling physicians to treat cancer-related diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 30 Acorn Park Drive
  • 6th Floor
  • Cambridge, MA 02140
  • United States
+1 (617) 000-0000

FogPharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FogPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 04-Jan-2021 $23.3M 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 16-May-2018 0000 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 18-Aug-2017 $11M $11M 0000 Completed Generating Revenue
To view FogPharma’s complete valuation and funding history, request access »

FogPharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 0,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series A 1,434,062 $0.000100 $0.62 $7.75 $7.75 1x $7.75 11.99%
To view FogPharma’s complete cap table history, request access »

FogPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cell-penetrating mini proteins (CPMPs)designed to target cancer-causing proteins inside cancer cells and ne
Drug Discovery
Cambridge, MA
68 As of 2020
00000
0000 0000-00-00
00000000000 00000

0000 000

mco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volup
0000000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000 000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000 000000000
Geneva, Switzerland
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

FogPharma Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000 000000000000 Formerly VC-backed Geneva, Switzerland 000.00 000000&0 000.00
0000000 0000000000 Formerly VC-backed Toronto, Canada 0 00.000 000000&0 00.000
000 00000000000000 Venture Capital-Backed Philadelphia, PA 00 0000 00000000000 0000
000 000000000000 Venture Capital-Backed Birmingham, AL 00.000 0000000000 0 00.000
You’re viewing 5 of 39 competitors. Get the full list »

FogPharma Executive Team (9)

Name Title Board Seat Contact Info
Weiqing Zhou Co-Founder & Chief Operating Officer
Howard Stern Ph.D Chief Scientific Officer
John McGee Ph.D Scientific Founder, Associate Director & Head of De Novo Discovery
David Lane Ph.D Co-Founder
Gerard Hilinski Ph.D Co-Founder & Senior Scientist
You’re viewing 5 of 9 executive team members. Get the full list »

FogPharma Board Members (7)

Name Representing Role Since
Barbara Weber MD Self Board Member 000 0000
Dr. Lianyong Chen Ph.D 6 Dimensions Capital Board Member 000 0000
Edward Fitzgerald FogPharma Board Member 000 0000
Gregory Verdine Ph.D Self Co-Founder, President, Chief Executive Officer & Chairman 000 0000
Jeffrey Leerink SVB Leerink Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

FogPharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FogPharma Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
venBio Venture Capital Minority 000 0000 000000 0
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
Blue Pool Capital Family Office Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Horizons Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »